Celts welcome Celgene’s Patient access scheme for Vidaza, too
This article was originally published in Scrip
Celgene has finally secured a recommendation in Scotland for its bone marrow drug Vidaza (5-azacitidine) for treating myelodysplastic syndrome and leukaemia with a patient access scheme. The company eventually won a recommendation in England with the same tactic.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.